[A21-103] Avatrombopag (thrombocytopenia) - Addendum to Commission A21-31

Last updated 16.09.2021

Project no.:
A21-103

Commission:
Commission awarded on 10.08.2021 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Haematology

Indication:

Adult patients with severe thrombocytopenia and chronic liver disease who are scheduled to undergo an invasive procedure

Result of dossier assessment:

Unchanged after addendum:

  • Moderate or high bleeding risk of the invasive procedure: proof of considerable added benefit.
  • Low bleeding risk of the invasive procedure: added benefit not proven.
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2021-09-16 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form